2Moll R,Schiler DL,Franke WW. Identification of protein IT of the intestinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns[J] .J Cell Biot, 1990,111: 567～580.
3Dohmoto K, Hojo S, Fujita J,et al. Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines[J] .Lung Cancer, 2000,30(1): 55.
4Sheard MA, Vojtesek B, Simickova M,et al. Release of cytokeratin -18 and 19 fragments (TPS and CYFRA21-1 ) into the extracellular space during apoptosis[J] .J Cell Biochem, 2002,85(4): 670.
5Bodenmuller H. Technical evaluation of a new automated tumor marker assay: the enzymum-test CYFRA21-1[A]. Hapdor R. Tumor associated antigens, oncogene receptors, cytokines in tumor diagnosis and therapy at the beginning of the 90ths[M]. Zuckschwenlt: Verlag, 1992, 137～147.
4[3]Moll R,Schiler DL,Franke WW.Identification of protein IT of the in testinal cytoskeleton as a novel type I cytokeratin with unusual properties and expression patterns[J].J Cell Biot,1990,111:567～580.
5[4]Dohmoto K,Hojo S,Fujita J, et al.Mechanisms of the release of CYFRA21-1 in human lung cancer cell lines[J].Lung Cancer,2000,30(1):55.
6[5]Sheard MA,Vojtesek B,Simickova M,et al.Release if cytokeratin -18 and 19 fragments(TPS and CYFRA21-1)into the extracellular space during apoptosis[J].J Cell Biochem,2002,85(4):670.
7Brechot JM, Chevret S, Nataf J, et al. Diagnostic and prognostic value of Cyfra21-1 compared with other tumor markers in patients with non-small lung cancer: a prospective study of 116 patients. Eur J Cancer, 1997,33(3):385-391.
8Gaarenstroom KN, Bonfrer JM, Korse CM,et al. Value of Cyfra21-1 ,TPA and SCC-Ag in predicting extracervical disease and prognosis in cervical cancer.Anticancer Res, 1997,17(4B) :2955-2958.
5Maass JD, Hoffmannfazel A, Goeroeqh T, et al. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer. Anticancer Res, 2000, 20: 2241-2243.
6Kuropkat C, Lippert BM, Wemer JA. Follow-up with serum Cyfra21 - 1 inpatients with squamous cell carcinomas of the head and neck. Oncology, 2002, 63: 280-285.
7Doweck I, Barak M, Greenberg E, et al. Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg, 1995, 121: 177-181.
8Foa P, Fornier M, Miceli R, et al. Tumour markers CEA,NSE,SCC, TPA and CYFRA21-1 in respectable non-small cell lung cancer. Anticancer Res, 1999, 19: B3613-3618.
9Yen TC, Lin WY, Kao CH, et al. A study of a new tumour marker, CYFRA21M, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol, 1998, 23: 82-86.
10Ogawa T, Tsurusako Y, Kimura N, et al. Comparison of tumor markers in patients with squamous cell carcinoma of the head and neck. Acta Otolaryngol Suppl, 1999, 540: 72-76.
